TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Apr 23, 2021 09:07 JST
Source:
Eisai
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease
TOKYO, Apr 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Biogen (Nasdaq: BIIB) has disclosed, in its Q1 2021 Earnings Press Release issued on April 22, its current submission status of the Marketing Authorization Applications (MAA) for aducanumab, an investigational treatment for Alzheimer's disease, in countries other than the United States, Japan, and in Europe which have been announced previously.
In the first quarter of 2021 Biogen submitted a MAA to Ag?ncia Nacional de Vigil?ncia Sanit?ria (ANVISA) in Brazil for aducanumab an investigational treatment for Alzheimer's disease. This application is currently in queue for review.
Biogen also submitted MAAs for aducanumab to Health Canada, the Therapeutic Goods Agency in Australia, and Swissmedic in Switzerland, all of which are subject to agency validation of whether the applications are accepted.
Aducanumab is being jointly developed by Biogen and Eisai.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
July 02 2026 21:45 JST
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
July 02 2026 21:01 JST
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
June 17 2026 12:28 JST
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
More Press release >>
Latest Press Release
MHI Receives Order from Taiwan High Speed Rail Corporation for Maintenance Tools and Equipment for Yanchao Main Workshop
Jul 03, 2026 00:22 JST
Hitachi Rail completes acquisition of Clever Devices, expanding its portfolio of multi-modal transport solutions
Jul 02, 2026 23:15 JST
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
Jul 02, 2026 22:45 JST
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
Jul 02, 2026 22:01 JST
Fujitsu Group achieves gold medal in EcoVadis sustainability rating
Jul 02, 2026 15:00 JST
NEC drives digital transformation at Messer Gases in Brazil with Cisco advanced networking and security solutions
Jul 02, 2026 15:00 JST
JCB Contactless Payment Now Available on Taipei Metro
Jul 01, 2026 10:00 JST
Hitachi High-Tech opens Innovation Center Eindhoven in the Netherlands to accelerate open innovation
Jul 01, 2026 00:59 JST
Honda to Commemorate 40th Anniversary of Its First F1(TM) Title
Jul 01, 2026 00:48 JST
Honda Issues "Honda ESG Report 2026"
Jul 01, 2026 00:24 JST
Sharp Signs Memorandum of Understanding with Major Global Satellite Operator SES to Build a Collaboration in Satellite Communication Services
Jul 01, 2026 00:09 JST
Mitsubishi Motors to Bring Authentic Off-Road Performance to Life with its All-New Pajero Cross-Country SUV
Jun 30, 2026 23:46 JST
MHIEC Completes Rebuild of Nagasaki City East Plant
Jun 30, 2026 23:04 JST
NEC Recognized as a Specialist in Gartner(R) Emerging Market Quadrant for Physical AI Services - Established Vendors
Jun 30, 2026 22:47 JST
DENSO and TUV Rheinland Japan Confirm the Practicality of Battery Passport for AESC's Energy Storage Product Using Actual Data
Jun 30, 2026 22:10 JST
Mitsubishi Shipbuilding Receives Order for the MAmmoSS(R) Ammonia Fuel Handling System
Jun 27, 2026 13:16 JST
MHI Study Results Indicate Potential Cost Reductions in the Decarbonization Value Chain Using Green Hydrogen and Ammonia Produced in India
Jun 27, 2026 13:00 JST
Foxconn and Sharp Signs Memorandum of Understanding for Strategic Collaboration in New Business Areas
Jun 27, 2026 12:44 JST
DENSO Group Formulates New Environmental Policy "Eco Vision 2035"
Jun 27, 2026 11:58 JST
JCB and PNB Launch New Platinum Credit Card, Empowering Consumers with Greater Value and Lifestyle Benefits
Jun 26, 2026 19:00 JST
More Latest Release >>